Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients
Author
dc.contributor.author
Figueroa, Guillermo
Author
dc.contributor.author
Acuña, Raul
Author
dc.contributor.author
Troncoso, Miriam
Author
dc.contributor.author
Portell, Dana P.
Author
dc.contributor.author
Toledo, Maria S.
Author
dc.contributor.author
Albornoz, Viviana
Author
dc.contributor.author
Vigneaux, Jorge
Admission date
dc.date.accessioned
2019-01-29T15:32:10Z
Available date
dc.date.available
2019-01-29T15:32:10Z
Publication date
dc.date.issued
1996
Cita de ítem
dc.identifier.citation
American Journal of Gastroenterology, Volumen 91, Issue 7, 2018, Pages 1395-1399
Identifier
dc.identifier.issn
00029270
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/161575
Abstract
dc.description.abstract
Objectives: We studied prospectively in a single-blind controlled manner the efficacy of 4-wk triple-antibiotic therapy, with amoxicillin (500 mg p.o., t.i.d.), metronidazole (250 mg p.o., t.i.d.), and bismuth subsalicylate tablets (524 mg p.o., q.i.d.), plus omeprazole (20 mg p.o., q.d.) and compared it with omeprazole (id) in the treatment of duodenal ulcer (DU) patients colonized with Helicobacter pylori. Methods: One hundred DU patients were entered prospectively over a 12-month period. Fifty-seven of them received triple therapy plus omeprazole and 43 received omeprazole alone. Clinical, endoscopic, and bacteriological evaluations were performed on admission and at 28 days, 4, 8, and 12 months after treatment. Results: After 4-wk treatment (day 28), the ulcer healing rate was high, but there was no significant difference between rates in the triple therapy and omeprazole groups (99% vs. 91%). In contrast, the long-term DU recurrence rate after 12- month follow-up was significantly